Table 1.
Details of the treatments given to the patient
| Month | Year | Treatment | Notice |
|---|---|---|---|
| 10 | 2013 | Primary and synchronous liver metastases → MDT | |
| Local treatment | |||
| 10 | 2013 | Short-course radiotherapy → abdominoperineal resection | |
| 11 | 2013 | Verification and progression of 23 liver metastases → MDT | |
| Disease control chemotherapy | |||
| 11–12 | 2013 | Capecitabine and oxaliplatin (CAPOX) x2, PR | KRAS, NRAS wild type |
| 1 | 2014 | Panitumumab added to CAPOX x1 | Anaphylactic reaction of oxaliplatin |
| 1–7 | 2014 | Panitumumab and capecitabine x7, CR x2 | |
| Follow-up in CR | |||
| 8 2 | 2014–2015 | Regular follow-up with CT/MRI, clinical examination and laboratory tests including tumor markers | |
| Liver resection and adjuvant-like therapy | |||
| 3 | 2015 | Biopsy-verified relapse of 3 liver metastases → MDT | |
| 4 | 2015 | Neoadjuvant panitumumab and capecitabine x1 | |
| 4 | 2015 | Liver resection (8 lesions) → MDT | |
| 5–9 | 2015 | Adjuvant-like panitumumab and capecitabine x6 | |
| Follow-up after resection/CR | |||
| 10 1 | 2015-2021 | Regular follow-up with CT/MRI, clinical examination and laboratory tests including tumor markers | |
CAPOX, capecitabine and oxaliplatin; MDT, Multidisciplinary Team assessment; PR, partial response according to RECIST 1.1; CR, complete response according to RECIST 1.1.